insights_auto
Výhled: 37.0 % optimistický·13.7 % pesimistický
Přejít na analýzuchevron_right
NVO:NYSE
Novo
38,16 US$
arrow_upward
+1,68%(+0,63) 1D
7. 10., 13:50:45 GMT-4 · USD
search
Všechny symboly
| Symbol | Cena | Změna | Změna (%) |
|---|
insights_autoGenerování hlavních statistik pro NVO…
Otevřít
37,57 US$
Max.
38,47 US$
Min.
37,51 US$
Trž. kap.
127,12 mld.
Prům. obj.
13,29 mil.
Objem
8,61 mil.
Dividenda
4,71 %
Čtvrtletní dividenda
0,45 US$
Datum ex dividenda
14. 8. 2026
Ukazatel P/E
9,68
52týd. max.
64,16 US$
52týd. min.
35,12 US$
EPS
3,94 US$
Beta
0,75
Akcie v oběhu
3,39 mld.
Počet zaměstnanců
67 tis.
Otevřít
37,57 US$
Max.
38,47 US$
Min.
37,51 US$
Trž. kap.
127,12 mld.
Prům. obj.
13,29 mil.
Objem
8,61 mil.
Dividenda
4,71 %
Čtvrtletní dividenda
0,45 US$
Datum ex dividenda
14. 8. 2026
Ukazatel P/E
9,68
52týd. max.
64,16 US$
52týd. min.
35,12 US$
EPS
3,94 US$
Beta
0,75
Akcie v oběhu
3,39 mld.
Počet zaměstnanců
67 tis.
Zpravodajské články
Z webových zdrojů a od partnerů z oblasti zpravodajství
News Corp
·
před 1 hodinou
Merck’s Keytruda Is Dealt a Legal Setback. It’s Good News for This Biotech Stock.
Zacks
·
před 1 hodinou
VKTX Advances Obesity Program With New Oral Maintenance Study
AD HOC NEWS
·
před 2 hodinami
Novo Nordisk stock gains 2.89 percent after-hours to EUR 34.18
Traders Union
·
před 2 hodinami
Novo Nordisk shares gain more than 2% after ongoing buyback program and cost-saving measures
Profil
Novo is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily diabetes and obesity medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s.
Novo employs approximately 68,800 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings which holds 28% of its shares and a majority of its voting shares.
Novo is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten.
Novo is the largest pharmaceutical company in Denmark. In 2023, Novo's market capitalization exceeded the GDP of Denmark's domestic economy, and it became the highest valued company in Europe. Wikipedia
Informace o Novo
Generální ředitelMaziar Mike Doustdar
Zaměstnanci66,7 tis.
Založeno21. 12. 1923
ÚstředíBagsværd, Hovedstaden, Dánsko
Odvětví-